News Column

Study Results from J. Lee and Colleagues in the Area of Breast Cancer Reported (A class I histone deacetylase inhibitor, entinostat, enhances...

August 25, 2014



Study Results from J. Lee and Colleagues in the Area of Breast Cancer Reported (A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Research findings on Oncology are discussed in a new report. According to news reporting originating from Waltham, Massachusetts, by NewsRx correspondents, research stated, "Although there are effective HER2-targeted agents, novel combination strategies in HER2-overexpressing breast cancers are needed for patients whose tumors develop drug resistance. To develop new therapeutic strategy, we investigated the combinational effect of entinostat, an oral isoform-selective histone deacetylase type I inhibitor, and lapatinib, a HER2/EGFR dual tyrosine kinase inhibitor, in HER2+ breast cancer cells."

Our news editors obtained a quote from the research, "We assessed the combinational synergistic effect and its mechanism by CellTiter Blue assay, flow cytometry, anchorage-independent growth, quantitative real-time PCR, small interfering RNA, Western blotting, and mammary fat pad xenograft mouse models. We found that compared with entinostat or lapatinib alone, the two drugs in combination synergistically inhibited proliferation (P < 0.001), reduced in vitro colony formation (P < 0.05), and resulted in significant in vivo tumor shrinkage or growth inhibition in two xenograft mouse models (BT474 and SUM190, P< 0.001). The synergistic anti-tumor activity of the entinostat/lapatinib combination was due to downregulation of phosphorylated Akt, which activated transcriptional activity of FOXO3, resulting in induction of Bim1 (a BH3 domain-containing pro-apoptotic protein). Furthermore, entinostat sensitized trastuzumab/lapatinib-resistance-HER2-overexpressing cells to the trastuzumab/lapatinib combination and enhanced the anti-proliferation effect compare with single or double combination treatment. This study provides evidence that entinostat has enhanced anti-tumor effect in combination with HER2-targeted reagent, lapatinib, and resulting in induction of apoptosis by FOXO3-mediated Bim1 expression."

According to the news editors, the research concluded: "Our finding justifies for conducting a clinical trial of combinational treatment with entinostat, lapatinib, and trastuzumab in patients with HER2-overexpressing breast cancer resistant to trastuzumab-based treatment."

For more information on this research see: A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Research and Treatment, 2014;146(2):259-272. Breast Cancer Research and Treatment can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Breast Cancer Research and Treatment - www.springerlink.com/content/0167-6806/)

The news editors report that additional information may be obtained by contacting J. Lee, Syndax Pharmaceut Inc, Waltham, MA, United States. Additional authors for this research include C. Bartholomeusz, O. Mansour, J. Humphries, G.N. Hortobagyi, P. Ordentlich and N.T. Ueno (see also Oncology).

Keywords for this news article include: Antineoplastic Monoclonal Antibodies, Biotechnology, Drugs, Waltham, Therapy, Oncology, Xenograft, Trastuzumab, Massachusetts, United States, Breast Cancer, Nucleoproteins, Women's Health, Amidohydrolases, HER2 Inhibitors, Medical Devices, Enzyme Inhibitors, Xenotransplantion, Enzymes and Coenzymes

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters